Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01568346 · ClinicalTrials.gov registry record · Phase 3
Breast MRI for Newly Diagnosed Breast Cancer:Impact on Re-excision Lumpectomy
A Phase 3 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Phase 3
- Development phase
- 9
- Enrollment target
NCT01568346 is a Phase 3 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 9 participants.
The verdict
NCT01568346, a Phase 3 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study is being done to find out the number of surgical procedures required to achieve clear margins in women with newly diagnosed early stage breast carcinoma. The investigators are also looking at the number of additional biopsies performed before surgery, the mastectomy rate, detection of breast cancer on the opposite side (contralateral carcinoma), time form diagnosis to local therapy, and evaluation time to local recurrence.
Interventions
- OTHER MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-02 |
| Est. Completion | 2013-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01568346
The ClinicalTrials.gov registry entry for NCT01568346 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MRI is the first listed.
NCT01568346 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01568346 about?
NCT01568346 is a clinical study titled "Breast MRI for Newly Diagnosed Breast Cancer:Impact on Re-excision Lumpectomy". This study is being done to find out the number of surgical procedures required to achieve clear margins in women with newly diagnosed early stage breast carcinoma. The investigators are also looking at the number of additional biopsies performed before surgery, the mastectomy rate, detection of bre...
What is the current status of trial NCT01568346?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 9 participants. The study started on 2012-02. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01568346?
The interventions under investigation include: MRI (OTHER).
Who is sponsoring clinical trial NCT01568346?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.